Rodríguez-Violante M, Cervantes-Arriaga A, González-Latapí P, León-Ortiz P, de la Fuente-Sandoval C, Corona T

Idioma: Ingles.
Referencias bibliográficas: 45
Paginas: 227-234
Archivo PDF: 215.42 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: A population-based, prospective study. J Am Geriatr Soc. 2000;48:938-42.

2. Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: A review. Drugs Aging. 2008;25:665-82.

3. Mack J, Rabins P, Anderson K, et al. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry. 2012;20:123-32.

4. Armstrong RA. Visual symptoms in Parkinson’s disease. Parkinsons Dis. 2011:908306.

5. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson’s disease as disturbed external/internal perceptions: Focused review and a new integrative model. Mov Disord. 2005;20:130-40.

6. Maddock RJ, Buonocore MH. MR spectroscopic studies of the brain in psychiatric disorders. Curr Top Behav Neurosci. 2012; 11:199-251.

7. Zheng XN, Zhu XC, Ruan LX, et al. MRS study on lentiform nucleus in idiopathic Parkinson’s disease with unilateral symptoms. J Zhejiang Univ Sci. 2004;5:246-50.

8. Griffith HR, Okonkwo OC, O’Brien T, Hollander JA. Reduced brain glutamate in patients with Parkinson’s disease. NMR Biomed. 2008;21:381-7.

9. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745-52.

10. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: Report of an NINDS, NIMH work group. Mov Disord. 2007;22:1061-8.

11. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25:2649-53.

12. Fahn S, Elton RL. UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson’s Disease, Vol. 2. Florham Park, NJ: Macmillan Health Care Information 1987; 153-63, 293-304.

13. Kay SR, Opler LA, Lindenmayer JP. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13:261-76.

14. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14:260-4.

15. Collerton D, Taylor JP. Advances in the treatment of visual hallucinations in neurodegenerative diseases. Future Neurol. 2013;8:433-44.

16. Lenka A, Jhunjhunwala KR, Saini J, Pal PK. Structural and functional neuroimaging in patients with Parkinson’s disease and visual hallucinations: A critical review. Parkinsonism Relat Disord; 2015;21:683-91.

17. Pagonabarraga J, Soriano-Mas C, Llebaria G, López-Solá M, Pujol J, Kulisevsky J. Neural correlates of minor hallucinations in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:290-6.

18. Kiferle L, Ceravolo R, Giuntini M, et al. Caudate dopaminergic denervation and visual hallucinations: evidence from a 123I-FPCIT SPECT study. Parkinsonism Relat Disord. 2014;20:761-5.

19. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004;63:1409-16.

20. Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab. 2003;23:285-300.

21. Redgrave P, Prescott TJ, Gurney K. The basal ganglia: a vertebrate solution to the selection problem? Neuroscience. 1999; 89:1009-23.

22. Agarwal N, Renshaw PF. Proton MR spectroscopy-detectable major neurotransmitters of the brain: biology and possible clinical applications. AJNR Am J Neuroradiol. 2012;33:595-602.

23. Salter BC, Anderson KE, Weiner WJ. Psychosis in Parkinson’s disease: Case studies. Neurol Clin. 2006;24:363-9.

24. Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: High-dose challenge does not precipitate hallucinations. Neurology. 1998;50:515-17.

25. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson’s disease: A community-based study. Arch Neurol. 1999;56:595-601.

26. Fénelon G, Goetz, CG, Karenberg A. Hallucinations in Parkinson’s disease in the prelevodopa era. Neurology. 2006;66:93-8.

27. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2001;70:734-8.

28. Clarke CE, Lowry M. Basal ganglia metabolite concentrations in idiopathic Parkinson’s disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol. 2000;7:661-5.

29. Taylor-Robinson SD, Turjanski N, Bhattacharya S, et al. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson’s disease. Metab Brain Dis. 1999;14:45-55.

30. Clarke CE, Lowry M, Horsman A. Unchanged basal ganglia Nacetylaspartate and glutamate in idiopathic Parkinson’s disease measured by proton magnetic resonance spectroscopy. Mov Disord. 1997;12:297-301.

31. Kickler N, Krack P, Fraix V, et al. Glutamate measurement in Parkinson’s disease using MRS at 3 T field strength. NMR Biomed. 2007;20:757-62.

32. Cepeda C, Levine MS. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci. 1998;20:1-18.

33. West AR, Floresco SB, Charara A, Rosenkranz JA, Grace AA. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann N Y Acad Sci. 2003;1003:53-74.

34. David HN, Ansseau M, Abraini JH. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate- putamen and nucleus accumbens of “intact” animals. Brain Res Rev. 2005;50:336-60.

35. Morales I, Fuentes A, Ballaz S, Obeso JA, Rodriguez M. Striatal interaction among dopamine, glutamate and ascorbate. Neuropharmacology. 2012;63:1308-14.

36. Meoni P, Bunnemann BH, Kingsbury AE, Trist DG, Bowery NG. NMDA NR1 subunit mRNA and glutamate NMDA-sensitive binding are differentially affected in the striatum and pre-frontal cortex of Parkinson’s disease patients. Neuropharmacology. 1999;38:625-33.

37. Barker PB. N-acetyl aspartate--a neuronal marker? Ann Neurol. 200149:423-4.

38. Taylor MJ, Godlewska BR, Norbury R, Selvaraj S, Near J, Cowen PJ. Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate. Int J Neuropsychopharmacol. 2012;15:1541-6.

39. Bowen BC, Block RE, Sanchez-Ramos J, et al. Proton MR spectroscopy of the brain in 14 patients with Parkinson’s disease. AJNR Am J Neuroradiol. 1995;16:61-8.

40. Camicioli RM, Hanstock CC, Bouchard TP, Gee M, Fisher NJ, Martin WR. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson’s disease. Mov Disord. 2007;22:382-6.

41. Holshouser BA, Komu M, Möller HE, et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson’s disease: A multicenter pilot study. Magn Reson Med. 1995;33:589-94.

42. Zhou B, Yuan F, He Z, Tan C. Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson’s disease. Brain Imaging Behav. 2014;8:97-101.

43. Lucetti C, Del Dotto P, Gambaccini G, et al. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson’s disease patients. Neurol Sci. 2001;22:69-70.

44. Camicioli RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson’s disease patients without dementia. Neurosci Lett. 2004;354:177-80.

45. Nie K, Zhang Y, Huang B, et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson’s disease patients with mild cognitive impairment. Parkinsonism Relat Disord. 2013;19:329-34.